Trial progresses for vaccination for chikungunya virus
A vaccination for a mosquito-borne virus that has re-emerged in the Caribbean is headed for phase 2 clinical trials.
The National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health, is sponsoring trials of a vaccination for the chikungunya virus.
Phase 2 of the trial will enroll 400 adults in the Caribbean, where the virus has re-emerged. The chikungunya virus is spread by mosquito bites, and it can produce severe joint pain, fever and headache that typically last for a week but can persist for months or years.
There have been more than 621,000 cases reported in the Caribbean this year.
A handful of cases of chikungunya have been detected in the United States, so all potential blood donors are asked about exposure to the virus during their screening.